Full-Time

Brand Manager

Pediatric Nutrition Strategy & Execution

Updated on 7/23/2026

Deadline 7/31/26
Abbott

Abbott

10,001+ employees

Global healthcare company manufacturing medical devices

No salary listed

Mumbai, Maharashtra, India

Hybrid

On-site in Mumbai (BKC Building); 20% travel.

Category
Growth & Marketing (1)
Required Skills
Market Research

Get referred to Abbott

Find people who can refer or advise you

Requirements
  • MBA Marketing from reputed Institute.
  • Worked in Consumer Marketing function and having prior marketing experience in implementing marketing mix through medical detailing team.
  • Proven track record for designing, implementing and tracking impact of creative marketing programs through sales force.
  • Worked with healthcare/ nutrition categories.
  • New Product launch experience will be an advantage
  • Experience in sales function will be an added advantage
Responsibilities
  • Responsible for the topline and brand profitability
  • Execution of HCP (healthcare professional) promotion / BTL consumer activation / Digital activation / Trade promotion
  • Formulation of marketing strategies, Communication development for both Consumers and Healthcare practitioners.
  • Building strong Marketing programs to engage consumers/ HCPs effectively. Execute with help of cross functional teams.
  • Tracking and measuring the impact of the Marketing Programs.
  • Responsible to drive NEW identified avenue of growth for maternal nutrition brand and build consumer engagement platform for entire infant & maternal nutrition portfolio
  • Managing the Creative agencies - Medical and consumer to develop brand communication
  • Liaise with Market Research agencies to gather insights from consumers / Healthcare Practitioners to support Brand strategies and track Brand equity with consumers / HCPs
  • Build relationships into Key Opinion Leaders / influencers in identified Nutrition areas, and utilize relationships for shaping market initiatives, and for driving sales.
  • Support and drive sales – work in close partnership with Cross Functional teams to ensure marketing programs are driven consistently and in a high-quality manner.
Desired Qualifications
  • New Product launch experience will be an advantage
  • Experience in sales function will be an added advantage
  • Combination of OTC and HCP driven medical marketing experience will be an added advantage
  • Total desirable experience of 5-6 years in marketing
  • Worked with healthcare/ nutrition categories

Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lake Bluff, Illinois

Founded

1888

Get referred to Abbott

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cologuard drives mid-teens growth, adding $3.1B cancer diagnostics revenue in 2026.
  • 2026 EPS guidance raised to $5.45–$5.60, signaling confidence in MedTech pivot.
  • 54-year dividend increase streak reinforces S&P 500 Dividend Aristocrat status with $0.63 quarterly payout.

What critics are saying

  • ShinyHunters breached Cancer Diagnostics via vishing, stealing 30M+ PII rows and 1M+ SSNs in June 2026.
  • DOJ dropped criminal probe into Sturgis baby formula plant linked to 9 infant deaths after Trump's $500K stock buy.
  • Nutrition segment declined 3.1% in Q2 2026, threatening margin expansion if MedTech pivot stalls.

What makes Abbott unique

  • Abbott uniquely combines high-margin MedTech with cancer diagnostics via $21.5B Exact Sciences deal.
  • FreeStyle Libre dominates CGM market with 11% Q2 2026 sales jump to $2.19B.
  • Heart device franchise remains resilient amid elective procedure pressures due to electrophysiology focus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Professional Development Budget

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

6%

2 year growth

16%
CyberUpdates365
Jul 19th, 2026
Abbott data breach: ShinyHunters claims theft of 30 million patient records.

Abbott data breach: ShinyHunters claims theft of 30 million patient records. Healthcare giant Abbott Laboratories is investigating two separate cyber incidents this week, after the notorious extortion gang ShinyHunters claimed to have stolen tens of millions of records from the company's Cancer Diagnostics business. This Abbott cyber attack, now widely tracked as the ShinyHunters Abbott incident, has drawn significant attention due to the scale of records the group claims to have taken. A second, unrelated group is also claiming a separate breach of Abbott's LabCentral customer portal. Abbott has confirmed unauthorized access occurred, but disputes the scale of what attackers claim to have taken, and says the incidents have not disrupted patient care, manufacturing, or business operations. Table of Contents What ShinyHunters claims to have stolen. ShinyHunters told security outlet BleepingComputer that it broke into Abbott's systems through a vishing (voice phishing) attack targeting several employees in mid-June. The group claims this let it compromise a corporate Microsoft Entra single sign-on (SSO) account, which in turn gave it access to data across connected platforms including Salesforce, Microsoft 365, Google Workspace, SAP, ServiceNow, SharePoint, Databricks, and Coupa. According to the group's claims, the haul includes more than 30 million rows of customer personal data - names, emails, phone numbers, physical addresses, dates of birth, and over 1 million Social Security numbers. ShinyHunters further claims to have taken more than 22 million client notes containing doctor-patient conversations, over 20 million medical orders, plus internal contracts and NDAs. It's important to stress that none of this stolen data has actually been published, and researchers have not independently verified the scale of what the group claims. ShinyHunters added Abbott to its dark web extortion site, initially threatening to leak the data after July 18, before extending the deadline to July 21. Abbott's official response on the Exact Sciences breach. In an official statement, Abbott confirmed unauthorized access to a limited number of internal systems within its Cancer Diagnostics business specifically. This Abbott Exact Sciences breach involves legacy infrastructure inherited through the company's March 2026 acquisition of Exact Sciences, maker of the Cologuard and Cancerguard screening tests. Abbott says this legacy environment is separate from its core systems, and that the incident has not impacted product availability, manufacturing, lab operations, or patient care. Abbott says it activated its incident response plan, engaged outside cybersecurity experts, and notified law enforcement. The company also stated it does not currently expect the incident to have a material impact on its financial results. A second, separate claim: the LabCentral portal. A different threat actor, using the name ShadowByt3$, separately claims to have breached Abbott's Core Laboratory diagnostics business through its LabCentral customer portal, allegedly using compromised customer credentials to exploit what it described as a weak point in the environment starting July 4, 2026. This group claims to have taken manufacturing certificates, operating manuals, technical specifications, and regulatory documentation - but says no customer data was involved. Abbott disputes the significance of this claim entirely, stating that LabCentral is an externally hosted portal containing only publicly available reference documents, not sensitive business or customer information. Why ShinyHunters keeps targeting healthcare companies. This is far from ShinyHunters' first attack on the medtech sector. The group has run a sustained campaign since last year specifically targeting employees' Microsoft Entra, Okta, and Google SSO accounts through social engineering, and has previously been linked to breaches at Medtronic, OneMedical, AdaptHealth, iRhythm, and device maker Stryker - the latter targeted just after it recovered from a separate destructive attack. Healthcare and medtech companies remain attractive targets because a single compromised employee SSO login can act as a master key to dozens of connected SaaS platforms holding sensitive patient and business data - often without triggering the kind of alarms a direct network intrusion would. How to protect against vishing-based SSO attacks. Since this attack chain relies on tricking employees over the phone rather than exploiting software bugs, defenses need to focus on identity and process: * Enforce phishing-resistant MFA on SSO: FIDO2 hardware keys or platform authenticators can't be relayed over a phone call the way an SMS or voice-read OTP code can. * Verify help-desk reset requests out-of-band: Many vishing attacks target IT help desks directly, impersonating employees to request password or MFA resets - require a secondary verification channel before any reset. * Monitor SaaS app access patterns: A compromised SSO account often shows unusual login locations or bulk data exports across connected apps like Salesforce or SharePoint - anomaly detection here can catch attacks in progress. * Segment legacy acquired systems: As seen here, systems inherited through acquisitions (like Exact Sciences) are common weak points - audit and isolate them promptly rather than leaving them loosely connected to core infrastructure. Frequently asked questions. Was I affected by the Abbott data breach? If you've had contact with Abbott's Cancer Diagnostics or Exact Sciences business - as a patient, customer, or through doctor-patient notes - your data may be among what ShinyHunters claims to have stolen, though this remains unverified and unpublished at this time. Who is ShinyHunters? ShinyHunters is an extortion gang that has run a sustained campaign since 2025 targeting corporate SSO accounts (Microsoft Entra, Okta, Google) through social engineering, previously linked to breaches at Medtronic, iRhythm, Stryker, and 7-Eleven. Has Abbott confirmed the full scope of the breach? Abbott has confirmed unauthorized access to a limited number of internal Cancer Diagnostics systems but has not confirmed the scale of data ShinyHunters claims to have stolen, which remains unverified by independent researchers. Is Abbott's LabCentral portal breach serious? Abbott disputes this separately claimed incident's significance, stating the LabCentral portal only contains publicly available technical documents, not sensitive customer or business data. Reported by CyberUpdates365 desk. Delivering the latest insights on enterprise security, federal AI directives, and the future of IT infrastructure. Follow Cyber Updates 365 for daily updates on how technology is reshaping the corporate landscape. * Uday Patil Cybersecurity Expert | DevOps Engineer Founder and lead author at CyberUpdates365. Specializing in DevSecOps, cloud security, and threat intelligence. My mission is to make cybersecurity knowledge accessible through practical, easy-to-implement guidance. Strong believer in continuous learning and community-driven security awareness.

Bulletproof Servers
Jul 18th, 2026
Abbott Laboratories probes two cyber incidents amid extortion claims

Abbott Laboratories probes two cyber incidents amid extortion claims. Abbott Laboratories is investigating two separate cybersecurity incidents after confirming unauthorized access to internal legacy Exact Sciences systems in its Cancer Diagnostics business, while also investigating a separate claim that attackers breached its LabCentral portal and stole company data. The company confirmed the Cancer Diagnostics incident after the ShinyHunters extortion gang added Abbott to its data leak site, initially threatening to publish allegedly stolen data after July 18 unless the company negotiated with the group, before later extending the deadline to July 21. When BleepingComputer asked Abbott about the alleged ShinyHunters incident, Abbott directed BleepingComputer to a statement published on its website. "Abbott is investigating a cyber incident in which there was unauthorized access to a limited number of internal systems in our Cancer Diagnostics business only," the company said. "This does not impact any business operations, product or product availability, manufacturing or lab operations, or our ability to serve patients." Abbott added that the security incident has not impacted any other Abbott businesses or systems, and said the legacy Exact Sciences systems are separate from Abbott's. The company said it activated its incident response procedures after it learned of the incident, engaged cybersecurity experts, and notified law enforcement. Abbott also stated that it does not expect the incident to have a material impact on its business or financial results. ShinyHunters claimed to BleepingComputer that it gained access through a vishing attack targeting several Abbott employees in mid-June. According to the threat actor, the attack allowed it to compromise a Microsoft Entra single sign-on (SSO) account and gain access to internal systems. Since last year, the extortion group has been conducting social engineering campaigns that target employees' Microsoft Entra, Okta, and Google SSO accounts. After gaining access to a corporate SSO account, the threat actors steal data from connected SaaS applications such as Salesforce, Microsoft 365, Google Workspace, SAP, Slack, Adobe, Atlassian, Zendesk, Dropbox, and many others. The extortion gang has been increasingly targeting medtech companies, including Medtronic, OneMedical, and AdaptHealth. BleepingComputer has learned that ShinyHunters was also behind the iRhythm data breach and targeted Stryker soon after the company recovered from a destructive Iranian data-wiping attack. When asked what data was allegedly stolen, ShinyHunters claimed it exfiltrated data from Microsoft Entra, ServiceNow, SharePoint, Databricks, and Coupa, including internal documents, contracts, and customer information. The threat actor further claimed to have stolen more than 30 million rows of customer personally identifiable information (PII) from multiple datasets containing names, email addresses, phone numbers, physical addresses, dates of birth, and more than one million Social Security numbers. The group also claimed to have stolen over 22 million client notes containing doctor-patient conversations, more than 20 million medical orders, and customer agreements and NDAs. BleepingComputer has not independently verified the threat actor's claims regarding the stolen data. The second incident involves a threat actor known as ShadowByt3$, who contacted BleepingComputer claiming to have breached Abbott's Core Laboratory diagnostics business through its LabCentral customer portal. The threat actor said it breached the unit via its LabCentral customer portal using compromised customer credentials after identifying what it described as a "weak point" in the environment. According to the threat actor, they gained access on July 4, 2026, after which they slowly exfiltrated files by targeting API endpoints. ShadowByt3$ claims the stolen data includes CE manufacturing certificates, operation manuals, technical specifications, regulatory documentation, product requirement archives, calibrator value assignments, assay files, and other product documentation related to Abbott's laboratory diagnostic systems. The group says no customer data was stolen, but claims it obtained sensitive business documents and intellectual property. It also provided BleepingComputer with screenshots and a file listing as purported proof of the intrusion. Abbott confirmed to BleepingComputer that it is aware of the "potential" cyber incident but disputed the threat actor's characterization of the data it claims to have stolen, stating that all data stored in the environment is public and not sensitive. "LabCentral is an externally facing third-party hosted portal used by Abbott's core laboratory diagnostics business," an Abbott spokesperson told BleepingComputer. "It houses publicly available technical product reference documents, including operating manuals, troubleshooting checklists and product specifications, and does not contain proprietary/sensitive customer or business information." At this time, neither ShinyHunters nor ShadowByt3$ has publicly released data they claim to have stolen from Abbott.

MedTech Markets
Apr 29th, 2026
Abbott receives FDA clearance/ce Mark for AI-powered Ultreon 3.0.

Abbott receives FDA clearance/ce Mark for AI-powered Ultreon 3.0. April 29, 2026 | MedTech News Alert (April 28, 2026) Abbott announced FDA clearance and CE Mark approval for its next-generation, artificial-intelligence (AI)-powered coronary imaging platform - the Ultreon 3.0. The new platform incorporates optical coherence tomography (OCT) that provides physicians real-time planning guidance during minimally invasive percutaneous coronary intervention (PCI) to open blocked coronary arteries. Ultreon 3.0 technology allows physicians to use OCT images to more clearly view a patient's arterial blockages using AI technology. AI assesses the type of plaque causing the blockage and assists the physician in choosing the best location and size of the stent for optimal improvement in blood flow. Ultreon 3.0 features advanced software providing one-second OCT pullback - a high-speed infrared light-based imaging technique - capable of capturing detailed cross-sectional views of the coronary artery and offering higher resolution readings compared to traditional intravascular ultrasound (IVUS) that has low or zero contrast. (Limiting use of contrast may be important for some patients, such as those with kidney disease.) According to Abbott, a summary of core benefits of the Ultreon 3.0 AI-driven software include: * A clear understanding of the size, shape, and location of a coronary blockage, allowing optimal stent placement to maximize blood flow and guide treatment planning. * A post-procedure assessment to ensure the stent improved blood flow in the artery. * A streamlined setup and enhanced AI-automated insights that simplify physicians' workflow. * Easily acquired images from inside blood vessels and ability to efficiently plan procedures, specifically tailored for patients with complex coronary disease. Comments from Abbott's chief medical officer of the company's vascular business, Ethan Korngold, M.D.: "Complemented by our leading coronary portfolio, Ultreon 3.0 makes OCT imaging more intuitive and powerful for physicians, reimagining imaging into a tool for precision-guided intervention before and after procedures. Advancements like Ultreon 3.0 showcase Abbott's leadership in AI-powered imaging and as a trusted partner in delivering smarter, more personalized coronary care." According to Abbott, complex PCI is a specialized procedure performed in more than 600,000 patients annually in the U.S. and is used to treat severe coronary artery disease involving the treatment of challenging lesions - or plaques - that have built up in a patient's coronary arteries. Some patients may require multiple stents to address lesions.

The Edge Malaysia
Apr 10th, 2026
Jury orders Abbott to pay US$53 mil in pre-term infant formula trial, says Chicago Tribune

Jury orders Abbott to pay US$53 mil in pre-term infant formula trial, says Chicago Tribune. 10 Apr 2026, 12:11 pm A Chicago jury is said to have ordered Abbott Laboratories to pay Abbott Laboratories US$53 million (RM210.98 million) in compensation to a group of families over its infant formula milk which can allegedly cause a potentially deadly bowel disease. CHICAGO (April 10): A jury in Chicago on Thursday said Abbott Laboratories must pay US$53 million (RM210.98 million) in compensatory damages to a group of families that had accused the company of failing to warn that its formula for premature infants can cause a potentially deadly bowel disease, according to the Chicago Tribune. The verdict came at the end of a lengthy trial in Cook County circuit court, the latest among hundreds of lawsuits alleging that Abbott's cow's milk-based formula products for pre-term infants can cause necrotising enterocolitis, or NEC. Four families' lawsuits were consolidated for trial. The jury will meet again on Friday to determine how much Abbott must pay in punitive damages, according to the Tribune. A spokesperson for Abbott did not immediately respond to a request for comment. Abbott has denied that the products, which it says are essential for premature babies when their mothers cannot produce enough breast milk, cause NEC. NEC, which causes the death of bowel tissue, mostly affects premature newborns and has an estimated mortality rate of more than 20%. The children, who were born in Chicago-area hospitals between 2012 and 2019, developed NEC but survived, according to their lawsuits. Three required surgery, and all live with ongoing health problems, according to the filings. Hundreds more lawsuits. Nearly 1,000 lawsuits have been filed against Abbott, which makes Similac formulas, and Enfamil manufacturer Mead Johnson, a unit of Reckitt. More than 700 of the cases are centralised in an Illinois federal court, with others pending in state courts in states including Illinois, Missouri and Pennsylvania. The products in question are cow's milk-based formula and products for fortifying mother's milk that are specially made for infants in hospital settings, not ordinary formula available to consumers in stores. Illinois-based Abbott also makes medical devices, adult and child nutrition products and medicines. The companies have said that while breast milk protects against NEC, their formulas do not cause it, and that the benefits of breast milk have long been known to clinicians. Abbott CEO Robert Ford suggested in 2024 that the pre-term products might become unavailable because of the litigation. US regulatory agencies and a working group of scientists convened by the National Institutes of Health said in a joint report in 2024 that current evidence supports the hypothesis that it is the absence of breast milk rather than exposure to formula that is associated with an increase in incidence of NEC. Trial results mixed. The companies have had a mixed record in the few cases to go to trial thus far. In 2024, a jury in St Clair County, Illinois ordered Mead Johnson to pay US$60 million to the mother of a premature baby who died after being fed the company's Enfamil baby formula. A few months later, a St Louis jury ordered Abbott to pay US$495 million in damages in another case. Both verdicts have been appealed. The American Academy of Pediatrics filed a brief supporting Mead Johnson in its appeal of the verdict against it last year, saying that formula is part of the standard of care for premature babies. Abbott and Mead Johnson prevailed in one trial in Missouri state court in October 2024, but the judge in that case ordered a new trial after finding that lawyers for the defendants had acted improperly. That ruling is also on appeal. In March, a Florida state judge dismissed a NEC case slated for an upcoming trial after finding that an additional warning to the family's doctors would not have changed their decision to use the formula. No cases have proceeded to trial in federal court, as the judge overseeing that litigation has dismissed three of the four cases selected for bellwether trials. In the most recent dismissal in October, the judge said that Abbott had presented substantial evidence on the need for the formula and shown the plaintiffs' proposed alternative was unfeasible. Uploaded by Felyx Teoh

The Outlook Online
Apr 10th, 2026
Keller Postman secures $70 million in verdicts for all four plaintiffs in historic Abbott formula trial.

Keller Postman secures $70 million in verdicts for all four plaintiffs in historic Abbott formula trial. PR Newswire Today at 3:41pm PDT CHICAGO, April 10, 2026 /PRNewswire/ - Keller Postman has secured a jury verdict of $70 million for four infants who suffered necrotizing enterocolitis ("NEC") as a result of being fed Similac Special Care. Defendant Abbott Laboratories, which manufactures Similac Special Care, was held liable by a unanimous jury for the defective design of its product, for failing to warn of the risk of NEC posed by it, and for the company's negligence leading to the infants' injuries. "The jury's verdicts on behalf of these four infants confirm once again what Abbott has known for years and chosen to ignore: that Abbott's cow's milk-based formula causes NEC in premature infants, often with devastating and irreversible consequences. Four families walked into that courtroom asking for justice, and four families received it. We are so proud to have stood beside them, and we are not done," said Ben Whiting, Senior Partner at Keller Postman. "For decades, Abbott Laboratories has shown a flagrant disregard for the health of the most fragile infants," said Amelia Frenkel, Partner at Keller Postman. "We hope that this verdict is a wakeup call to the company: Business as usual cannot continue. Safety has to come first for every preterm baby born today and tomorrow and into the future." The four cases were filed on behalf of four pre-term babies born at Chicago-area hospitals. They are among more than 1,700 lawsuits Abbott faces nationally over whether its cow's milk-based preterm infant formula causes NEC - a life-threatening condition in which tissue lining the intestine becomes inflamed and dies. This is the first time Abbott has faced a verdict in Illinois state court. Today's verdict builds on Keller Postman's landmark 2024 victory - a $60 million jury verdict against Mead Johnson, the first trial ever to hold a cow's milk-based formula manufacturer accountable for causing NEC in premature infants. Together, these outcomes send an unmistakable message: manufacturers who have long known of the dangers of their products and continued to market them to the most vulnerable infants will be held accountable. Keller Postman is representing thousands of families across the United States, with cases filed in Illinois, California, Florida, Pennsylvania, and Missouri. The firm will continue to litigate aggressively to ensure that its clients receive just compensation and that future parents are fully informed that breast milk, donor milk, and human milk-based formulas offer safer alternatives to defendants' products for preterm infants. Keller Postman's attorney team includes partners Ben Whiting and Amelia Frenkel, counsel Jamie Price, and associate Laura Shannon. At trial, they were joined by an Olson Grimsley trial team including Sean Grimsley, Kenzo Kawanabe, Abigail Hinchcliff, and Samara Hoose. About Keller Postman: Keller Postman is a national law firm dedicated to representing plaintiffs in the largest and most significant mass actions in the country. The firm's first-class legal team committed case managers, and tech-forward approach to complex litigation allow Keller Postman to outwork and out-innovate the other side. Its attorneys consistently deliver justice to families, consumers, veterans, and others injured by powerful defendants. SOURCE Keller Postman LLC This is a paid placement. For further inquiries, please contact PR Newswire directly.